Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences (VTYX -6.72%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and neurodegenerative diseases, released its second-quarter 2025 results on August 7, 2025. EPS (GAAP) was $0.38, which exceeded the analyst consensus estimate of $(0.47) GAAP.

Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare Conference, New York Fireside ChatDate: Thursday, June 5, 2025 Time: 12:50-1:20 PM ET A webcast of the event will be available in the Investors and News section of the Ventyx website at  www.ventyxbio.com.

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted recent pipeline and business progress. “Ventyx has established itself as the leader in discovery and development of NLRP3 inhibitors with two novel compounds, VTX3232 and VTX2735 progressing through Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications - disease states thought to be driven by pathologic activation of the NLRP3 inflammasome,” said Raju Mohan, PhD, President and Chief Executive Officer.

Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD and Don Frail, PhD. The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in neurodegenerative and cardiometabolic diseases.

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer.

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.

On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.